While Apellis Pharmaceuticals Inc has underperformed by -0.05%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, APLS fell by -53.81%, with highs and lows ranging from $43.76 to $16.10, whereas the simple moving average fell by -29.12% in the last 200 days.
On May 09, 2025, Raymond James Downgraded Apellis Pharmaceuticals Inc (NASDAQ: APLS) to Outperform. A report published by BofA Securities on May 09, 2025, Downgraded its rating to ‘Neutral’ for APLS. Cantor Fitzgerald also rated APLS shares as ‘Overweight’, setting a target price of $44 on the company’s shares in an initiating report dated April 29, 2025. Morgan Stanley initiated its ‘Equal-Weight’ rating for APLS, as published in its report on November 21, 2024. RBC Capital Mkts’s report from October 25, 2024 suggests a price prediction of $25 for APLS shares, giving the stock a ‘Sector Perform’ rating. William Blair also rated the stock as ‘Outperform’.
Analysis of Apellis Pharmaceuticals Inc (APLS)
Further, the quarter-over-quarter decrease in sales is -3.21%, showing a negative trend in the upcoming months.
One of the most important indicators of Apellis Pharmaceuticals Inc’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of -103.82% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 3.62, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and APLS is recording 2.63M average volume. On a monthly basis, the volatility of the stock is set at 4.01%, whereas on a weekly basis, it is put at 1.13%, with a gain of 0.84% over the past seven days. Furthermore, long-term investors anticipate a median target price of $35.35, showing growth from the present price of $19.26, which can serve as yet another indication of whether APLS is worth investing in or should be passed over.
How Do You Analyze Apellis Pharmaceuticals Inc Shares?
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 17.76%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 100.11% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
APLS shares are owned by institutional investors to the tune of 100.11% at present.
